Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics.

@article{Kovarik2003ClinicalDO,
  title={Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics.},
  author={John M. Kovarik and Adele No{\`e} and St{\'e}phane Berthier and Louis McMahon and Wayne K. Langholff and Alan S Marion and Peter Friedrich Hoyer and Robert B. Ettenger and Christiane Rordorf},
  journal={Journal of clinical pharmacology},
  year={2003},
  volume={43 2},
  pages={141-7}
}
The immunosuppressant everolimus used in organ transplantation is formulated as a conventional tablet for adults and a dispersible tablet that can be administered in water for pediatric use. As part of the pediatric clinical development program, the relative bioavailability and food effect for the dispersible tablet were evaluated in healthy adult subjects as a prelude to characterizing the steady-state pharmacokinetics in pediatric kidney allograft recipients. In a randomized, open-label… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…